This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2010 Aug;71(3):139-42.

doi: 10.1055/s-0029-1242756. Epub 2010 Feb 1.

Glioblastoma invasion, cathepsin B, and the potential for both to be inhibited by auranofin, an old anti-rheumatoid arthritis drug

R E Kast¹

Affiliations

PMID: 20127591
DOI: 10.1055/s-0029-1242756

Review

Glioblastoma invasion, cathepsin B, and the potential for both to be inhibited by auranofin, an old anti-rheumatoid arthritis drug

R E Kast. Cent Eur Neurosurg. 2010 Aug.

. 2010 Aug;71(3):139-42.

doi: 10.1055/s-0029-1242756. Epub 2010 Feb 1.

Author

R E Kast¹

Affiliation

¹ Psychiatry, University of Vermont, 22 Church Street, Burlington, VT 05401, USA. rekast@email.com

PMID: 20127591
DOI: 10.1055/s-0029-1242756

No abstract available

PubMed Disclaimer

Similar articles

Caffeine suppresses the progression of human glioblastoma via cathepsin B and MAPK signaling pathway.
Cheng YC, Ding YM, Hueng DY, Chen JY, Chen Y. Cheng YC, et al. J Nutr Biochem. 2016 Jul;33:63-72. doi: 10.1016/j.jnutbio.2016.03.004. Epub 2016 Mar 29. J Nutr Biochem. 2016. PMID: 27260469
TBK1-targeted suppression of TRIF-dependent signaling pathway of toll-like receptor 3 by auranofin.
Park SJ, Lee AN, Youn HS. Park SJ, et al. Arch Pharm Res. 2010 Jun;33(6):939-45. doi: 10.1007/s12272-010-0618-2. Epub 2010 Jul 6. Arch Pharm Res. 2010. PMID: 20607500
New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications.
Sannella AR, Casini A, Gabbiani C, Messori L, Bilia AR, Vincieri FF, Majori G, Severini C. Sannella AR, et al. FEBS Lett. 2008 Mar 19;582(6):844-7. doi: 10.1016/j.febslet.2008.02.028. Epub 2008 Feb 21. FEBS Lett. 2008. PMID: 18294965
Inhibition of Thioredoxin-Reductase by Auranofin as a Pro-Oxidant Anticancer Strategy for Glioblastoma: In Vitro and In Vivo Studies.
Chmelyuk N, Kordyukova M, Sorokina M, Sinyavskiy S, Meshcheryakova V, Belousov V, Abakumova T. Chmelyuk N, et al. Int J Mol Sci. 2025 Feb 27;26(5):2084. doi: 10.3390/ijms26052084. Int J Mol Sci. 2025. PMID: 40076706 Free PMC article. Review.
An Experimenter's Guide to Glioblastoma Invasion Pathways.
de Gooijer MC, Guillén Navarro M, Bernards R, Wurdinger T, van Tellingen O. de Gooijer MC, et al. Trends Mol Med. 2018 Sep;24(9):763-780. doi: 10.1016/j.molmed.2018.07.003. Epub 2018 Jul 30. Trends Mol Med. 2018. PMID: 30072121 Review.

See all similar articles

Cited by

Pro-Oxidant Auranofin and Glutathione-Depleting Combination Unveils Synergistic Lethality in Glioblastoma Cells with Aberrant Epidermal Growth Factor Receptor Expression.
Martinez-Jaramillo E, Jamali F, Abdalbari FH, Abdulkarim B, Jean-Claude BJ, Telleria CM, Sabri S. Martinez-Jaramillo E, et al. Cancers (Basel). 2024 Jun 25;16(13):2319. doi: 10.3390/cancers16132319. Cancers (Basel). 2024. PMID: 39001381 Free PMC article.
Organometallic gold(I) and gold(III) complexes for lung cancer treatment.
Zhang J, Li Y, Fang R, Wei W, Wang Y, Jin J, Yang F, Chen J. Zhang J, et al. Front Pharmacol. 2022 Sep 13;13:979951. doi: 10.3389/fphar.2022.979951. eCollection 2022. Front Pharmacol. 2022. PMID: 36176441 Free PMC article. Review.
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magné N, Marosi C, McDonald K, Muñoz M, Sassoon D, Pourgholami MH, Sardi I, Sella A, Srivenugopal KS, Tuccori M, Wang W, Wirtz CR, Halatsch ME. Kast RE, et al. Oncotarget. 2013 Apr;4(4):502-30. doi: 10.18632/oncotarget.969. Oncotarget. 2013. PMID: 23594434 Free PMC article. Review.
Systematic review of protein biomarkers of invasive behavior in glioblastoma.
Sayegh ET, Kaur G, Bloch O, Parsa AT. Sayegh ET, et al. Mol Neurobiol. 2014 Jun;49(3):1212-44. doi: 10.1007/s12035-013-8593-5. Epub 2013 Nov 24. Mol Neurobiol. 2014. PMID: 24271659
CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas.
Ma K, Chen X, Liu W, Chen S, Yang C, Yang J. Ma K, et al. Sci Rep. 2022 Mar 11;12(1):4295. doi: 10.1038/s41598-022-08346-2. Sci Rep. 2022. PMID: 35277559 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Georg Thieme Verlag Stuttgart, New York
Medical
- MedlinePlus Health Information